Shilpa Medicare Q2/H1 FY26: consolidated net profit jumps over 2.8x

Profit growth above 25%Exceptional itemResults restatedRelated-party transactionsResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹399.00

prior close

₹394.30

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-2.4% vs market

Pharmaceuticals peers, median of 157sector-0.0%-2.5% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.2

15m

-0.8

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.1-2.4-0.0-2.5

Next day

-5.3-0.2-5.1-0.4-4.8

-5.6+0.4-6.0-0.3-5.2

-9.0-0.4-8.6-1.0-8.0

-9.0-0.6-8.5-1.3-7.7

-10.7-0.9-9.8-1.5-9.2

-9.0-3.0-6.0-3.2-5.8

15d

-16.0-3.9-12.1-3.4-12.6

-19.0-4.8-14.2-4.0-15.0

-25.6-7.8-17.8-6.6-18.9

-18.3-7.2-11.0-8.5-9.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shilpa Medicare H1 FY26 results: consolidated revenue rose 9% YoY to Rs 691.4 crore while net profit jumped to Rs 90.95 crore from Rs 32 crore. Standalone revenue was nearly flat at Rs 227.4 crore with Q2 net profit at Rs 30.8 crore. H1 standalone net profit dipped 11% to Rs 51.5 crore, hit by Rs 6.75 crore exceptional impairment on advances and investments in foreign subsidiaries. NCLT sanctioned merger of wholly owned INM Technologies into the company, leading to restatement of prior period figures.

Likely market impact

Sharp consolidated earnings growth and completed merger are positives, but standalone profit dip and repeated foreign subsidiary write-downs may cap upside